|
Canada-0-MATTRESSES Azienda Directories
|
Azienda News:
- After FDA approval, Alkermes plans soft launch for antipsychotic . . .
The FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly genericised market
- THE ALL DAY LIE, BEGINNING A NEW TRADITION AT AZ!
AZ is a slave camp You are all ants living in the ant hill of life Foraging for a morsel here and there while Pascal and his ilk are eating their strawberry crepe breakfast at their French villa What a life!! No wonder the "All Day Lie" has been such a successful ongoing thread for years!!
- Scientia Vascular | Cafepharma
Medtronic (NYSE: MDT)+ announced today that it entered into a definitive agreement to acquire Scientia Vascular in a deal valued at $550 million Salt Lake City, Utah–based Scientia Vascular develops access products for treating complex neurovascular conditions Its portfolio features guidewires and catheters that Medtronic can seamlessly integrate into its existing suite of neurovascular
- Icotyde | Cafepharma
Johnson Johnson (J J) has reported new 52-week data from the Phase III ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and ICONIC-LEAD trials, evaluating the safety and efficacy of Icotyde (icotrokinra), a once-daily oral pill for moderate-to-severe plaque psoriasis
- midday briefs | Cafepharma
A quick midday brief on what’s moving across pharma, biotech, and medtech today
- sirolimus | Cafepharma
Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy
- Revolve Surgical | Cafepharma
Revolve Surgical announced today that it received FDA 510 (k) clearance for its surgical robot platform The Canada-based company develops what it describes as a first-in-class, zero-footprint surgical platform It provides robotic assistance to augment surgeons performing soft tissue procedures
- TTAM | Cafepharma
Anne Wojcicki, co-founder and former CEO of direct-to-consumer genetic testing company 23andMe, has succeeded in a bid to buy almost all the assets of the bankrupt company through a nonprofit set up by Wojcicki in May this year called TTAM
- Who’s next in the HQ? | Cafepharma Message Boards | Pharma Sales . . .
is the axe coming for lybalvi or aristada?
- Seismic Pharma | Cafepharma
New company formed to unlock value from Phase 3-ready and next-generation therapies for cardiogenic shock and acute heart failure Targeting completion of first Phase 3 study for istaroxime to enable NMPA registration by 2027 Advancing next-generation oral heart failure program towards first-in-human studies by 2027
|
|